Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05896670 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease
A Phase 2 study, sponsored by Oculis.
- Completed
- Registry status
- Phase 2
- Development phase
- 122
- Enrollment target
NCT05896670: Completed Phase 2 study, sponsored by Oculis.
NCT05896670 is a Phase 2 study that has completed, run by Oculis. The registered enrollment target is 122 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05896670, a Phase 2 study, has completed, sponsored by Oculis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 122 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn about licaminlimab (OCS-02) in the treatment of dry eye disease. The main question it aims to answer is if licaminlimab ophthalmic solution is more effective than vehicle in treating signs of dry eye disease.
Primary Outcome
Endpoints of signs of dry eye disease (staining, redness, Schirmer's test) at various time points throughout the study
Interventions
- DRUG licaminlimab
- OTHER vehicle of OCS-02
- OTHER Artificial tears
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2023-11-29 |
| Est. Completion | 2024-03-27 |
| Phase | Phase 2 |
What the finished NCT05896670 record still lists
NCT05896670 is an interventional study that assigns participants to a tested intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which licaminlimab is the first listed.
NCT05896670 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05896670 about?
NCT05896670 is a clinical study titled "Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease". The goal of this clinical trial is to learn about licaminlimab (OCS-02) in the treatment of dry eye disease. The main question it aims to answer is if licaminlimab ophthalmic solution is more effective than vehicle in treating signs of dry eye disease.
What is the current status of trial NCT05896670?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 122 participants. The study started on 2023-11-29. Estimated completion is 2024-03-27.
What interventions are being tested in trial NCT05896670?
The interventions under investigation include: licaminlimab (DRUG), vehicle of OCS-02 (OTHER), Artificial tears (OTHER).
Who is sponsoring clinical trial NCT05896670?
This trial is sponsored by Oculis, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05896670's enrollment target sits among peer trials
122 565th of 2000 higher than 1,434 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03363373 · 122 participants · Phase 2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- NCT03463954 · 122 participants · NA
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
- NCT04503265 · 122 participants · Phase 1
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- NCT04700527 · 122 participants · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI